Journal: Journal of Neuroinflammation

Article Title: Pathological hemodynamic changes and leukocyte transmigration disrupt the blood–spinal cord barrier after spinal cord injury

doi: 10.1186/s12974-023-02787-w

Figure Lengend Snippet: Leukocyte transmigration actively contributes to BSCB disruption. a Representative images of LPS-induced leukocytes (labeled by Alexa Fluor 700-conjugated GR-1) adhered to the lumen of vessels (labeled by 150 kDa FITC-dextran). Scale bar = 200 μm. b Quantification of activated leukocytes in the lumen of the dSV 12 h after LPS injection ( n = 6 mice). c Representative images of BSCB leakage (white arrow) induced by LPS-activated leukocytes at 12 h ( n = 4 independent experiments). Scale bar = 200 μm. d Representative immunofluorescence images of TJs in small vessels 24 h after LPS injection or application of SB225002 4 h post-SCI. Scale bar = 5 μm. e – g Quantification of gap density at TJs in ( d ). ( e ) Claudin-5; ( f ) occludin; ( g ) ZO-1 ( n = 5 mice, a total of 114, 121, 118, 167 vessels). h Time-lapse imaging of barrier leakage in the epicenter after acute SCI with SB225002 application. Scale bar = 200 μm. i Quantification of the integrated fluorescence intensity of 40 kDa TRITC-dextran extravasated from the dAV in ( h ). Data from the ctrl group were replotted from Fig. h ( n = 9 mice, or n = 6 in the ctrl group). Data are presented as the mean ± SEM; * P < 0.05, ** P < 0.01, **** P < 0.0001; nested, the Mann–Whitney test ( b ); one-way ANOVA ( e – g ); general estimated Equation ( i )

Article Snippet: The CXCR2 antagonist SB225002 (4 mg/kg, Merck) was injected intraperitoneally 2 h before the mice underwent SCI.

Techniques: Transmigration Assay, Disruption, Labeling, Injection, Immunofluorescence, Imaging, Fluorescence, MANN-WHITNEY

Journal: Natural Products and Bioprospecting

Article Title: Senkyunolide H reverses depression-induced breast cancer progression by regulating CXCR2

doi: 10.1007/s13659-025-00543-6

Figure Lengend Snippet: Effect of CXCR2 expression on the cancer-promoting effect of depression. A WB validation of the knockdown of the CXCR1 and CXCR2 proteins in Py230 cells. B Viability of Py230 cells in which CXCR1 or CXCR2 was knocked down 48 h after IL-8 treatment; n = 6. C Giemsa-stained colonies were visualized using an inverted microscope. D The number of cells was observed using an inverted microscope. E Flow chart of the in vivo experiments. F Open field test. G Forced swimming test. H – J Effect of a depressed mouse model on tumor growth in Py230 cells with CXCR1 or CXCR2 knockdown; n = 10. K WB of tumor tissue. The data are presented as the means ± SDs; * P < 0.05, ** P < 0.01, *** P < 0.001 compared with the 0 ng/ml IL-8 group (in vitro) or NC group (in vivo); # P < 0.05, ### P < 0.001 compared with the NC group (in vitro) or CUMS-NC group (in vivo)

Article Snippet: Currently, monoclonal antibodies targeting IL8 (e.g., HuMax-IL8 of Bristol Myers Squibb and ABX-CXCL8 of Abgenix) and receptor inhibitors targeting CXCR2 (e.g., Navarixin of Merck & Co., Inc., AZD5069 of AstraZeneca, and SX-682 of Syntrix Biosystems) have been used to treat advanced tumors; however, clinical studies have shown that the efficacy of these drugs is inconsistent [ – ].

Techniques: Expressing, Biomarker Discovery, Knockdown, Staining, Inverted Microscopy, In Vivo, In Vitro

Journal: Natural Products and Bioprospecting

Article Title: Senkyunolide H reverses depression-induced breast cancer progression by regulating CXCR2

doi: 10.1007/s13659-025-00543-6

Figure Lengend Snippet: Effect of senkyunolide H on the tumor-promoting effect of IL-8 in vitro. A Molecular docking of senkyunolide H with the CXCR2 protein. B CETSA results; n = 3. C Viability of Py230 cells treated with or without IL-8 at different concentrations of senkyunolide H for 48 h; n = 6. D Giemsa-stained colonies were observed under an inverted microscope. E Effects of different IL-8 or senkyunolide H concentrations on cell growth. F Effects of IL-8 and/or senkyunolide H on protein expression in Py230 cells; n = 3. The data are presented as the means ± SDs; * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the NC group or 0 ng/ml IL-8 group; # P < 0.05, ## P < 0.01, and ### P < 0.001 compared with the 100 ng/ml IL-8 group

Article Snippet: Currently, monoclonal antibodies targeting IL8 (e.g., HuMax-IL8 of Bristol Myers Squibb and ABX-CXCL8 of Abgenix) and receptor inhibitors targeting CXCR2 (e.g., Navarixin of Merck & Co., Inc., AZD5069 of AstraZeneca, and SX-682 of Syntrix Biosystems) have been used to treat advanced tumors; however, clinical studies have shown that the efficacy of these drugs is inconsistent [ – ].

Techniques: In Vitro, Staining, Inverted Microscopy, Expressing